


PHARMACEUTICAL 2017

uniQure N.V. Rank 139 of 313







PHARMACEUTICAL 2017

uniQure N.V. Rank 139 of 313



The relative strengths and weaknesses of uniQure N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of uniQure N.V. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 36% points. The greatest weakness of uniQure N.V. is the variable Research and Development, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is -143%, being 273% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	143,946
Cost of Goods Sold	0
Intangible Assets	8,789
Liabilities, Current	22,721
Liabilities, Non-Current	103,913
Other Assets	1,828
Other Compr. Net Income	271
Other Expenses	3,317
Other Liabilities	0
Other Net Income	1,889
Property and Equipment	35,702
Research and Development	72,510
Revenues	26,563
Selling, General and Administrative Expense	25,999

Output Variable	Value in 1000 USD
Assets	190,265
Liabilities	126,634
Expenses	101,826
Stockholders Equity	63,631
Net Income	-73,374
Comprehensive Net Income	-73,238
Economic Capital Ratio	-143%

